Business Combinations Hudson Narrative (Details) - USD ($) $ in Millions	3 Months Ended											12 Months Ended
	Dec. 31, 2017		Sep. 30, 2017		Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016		Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Business Acquisition [Line Items]
Borrowings on revolving credit facilities												$ 302.2		$ 3.8		$ 68.8
Sales	$ 306.0	[1]	$ 240.5	[1]	$ 238.2	$ 204.1	$ 214.4	$ 203.9		$ 247.1	$ 193.8	988.8	[1]	859.2		1,040.2
Operating Income (Loss)	21.3	[1],[2]	10.5	[1]	$ 9.9	$ 0.3	$ 2.3	$ 20.1	[3]	$ 34.9	$ 0.1	42.0	[1],[2],[4],[5]	57.4	[5],[6]	(183.2)	[5],[7]
Amortization expense												15.0		$ 11.9		$ 17.3
Business Combination, Acquisition Related Costs												10.1
Hudson [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred												419.5
Business Combination Consideration Transferred Estimated Working Capital Amount credit												6.0
Business Combination, Consideration Transferred, Acquisition-related Tax Benefits (credit)												3.5
Borrowings on revolving credit facilities												300.0
Sales	51.9		6.1									58.0
Operating Income (Loss)	$ 5.2		$ 1.2									6.4
Amortization expense												3.3
Business Combination, Acquisition Related Costs												$ 9.0
Minimum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life												10 years
Minimum [Member] | Hudson [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life												2 years
Maximum [Member] | Hudson [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life												15 years

[1] Hudson, included in these results since the acquisition date, September 20, 2017, added net sales and operating income of $58.0 and $6.4 for the year ended December 31, 2017, including $6.1 and $1.2 in the third quarter and $51.9 and $5.2 in the fourth quarter, respectively.

[2] The fourth quarter of 2017 includes additional expense as a result of a litigation award in China. Refer to Note 18, Commitments and Contingencies, for further information.

[3] During the third quarter of 2016, we recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15.2 and Corporate SG&A expenses by $0.3, net of associated legal fees recorded in 2016. The 2016 operating income also includes impairment of goodwill and intangible assets totaling $1.2 as described in Note 3, Asset Impairments, to the consolidated financial statements.

[4] Includes acquisition-related expenses of $10.1 for the year ended December 31, 2017.

[5] Includes restructuring costs of $15.6, $10.9 and $12.2 for the years ended December 31, 2017, 2016 and 2015, respectively

[6] During the third quarter of 2016, we recovered for breaches of representations and warranties primarily related to warranty costs for certain product lines acquired in the 2012 acquisition of AirSep under the related representation and warranty insurance. For the year ended December 31, 2016, this reduced BioMedical segment’s cost of sales by $15.2 and Corporate SG&A expenses by $0.3, net of associated legal fees recorded in 2016. The 2016 operating income also includes asset impairment charges of $1.2 attributed to D&S.

[7] Includes asset impairment charges of $255.1 for the year ended December 31, 2015, attributed to E&C – $68.8, D&S – $2.0, and BioMedical – $184.3.